Telix Pharmaceuticals Limited
TLPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $8 | $3 | $2 | $2 |
| - Cash | $1 | $0 | $0 | $0 |
| + Debt | $1 | $0 | $0 | $0 |
| Enterprise Value | $8 | $3 | $2 | $2 |
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 55.8% | 213.9% | 2,007.6% | – |
| Gross Profit | $1 | $0 | $0 | -$0 |
| % Margin | 65.1% | 62.6% | 18.3% | -391.9% |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 12.5% | 4.6% | -58% | -922.5% |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 6.4% | 1% | -65% | -1,059.9% |
| EPS Diluted | 0.14 | 0.016 | -0.34 | -0.29 |
| % Growth | 769.6% | 104.7% | -17.2% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |